Ask AI
ProCE Banner Activity

Switch to Ulonivirine + Islatravir in Adults With Virologically Suppressed HIV-1: Phase IIb Trial

Conference Coverage
Slideset

Switch from BIC/FTC/TAF to weekly islatravir (20 mg) plus ulonivirine (100-400 mg) maintained viral suppression through Week 24 and was generally well tolerated in adults with virologically suppressed HIV.

Released: July 15, 2025

Expiration: January 14, 2026

Share

Provided by

Provided by Clinical Care Options, LLC  in partnership with the International AIDS Society

ProCE Banner

Supporters

Supported by educational grants from Gilead Sciences, Inc., Merck & Co., Inc., Rahway, NJ, USA, and ViiV Healthcare.

Gilead Sciences, Inc.

Merck & Co., Inc., Rahway, NJ, USA

ViiV Healthcare

Partners

IAS

ProCE Banner